Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 601 - 650 out of 12,743

Document Document Title
WO/2016/177300A1
Disclosed are a compound of formula I, and preparation method and intermediate thereof; the use of the compound of formula I in preparing a drug for treating viral infections; the use of the compound of formula I in preparing sofosbuvir ...  
WO/2016/174081A1
The present invention relates to novel pro-drugs of L-2'-deoxythreose nucleoside phosphonates, such as phosphoramidate, phosphorodiamidate and phospho-diester prodrugs. The invention also relates to a process for preparing these novel pr...  
WO/2016/176193A1
Disclosed herein is a method to specifically remove alloreactive T cells. In one example, the method includes culturing donor cells comprising donor T cells with recipient antigen presenting cells (APCs) to form a mixture of cells under ...  
WO/2016/123397A3
The present disclosure provides nucleoside analogs of Formula (I) or (II). The nucleoside analogs may show multiple tautomerism and may increase the mutation of an RNA and/or DNA (be mutagenic) of a virus or cancer cell. The multiple tau...  
WO/2016/168911A1
The present invention is directed to purine nucleoside analogs of the general formula (I) or salts and pharmaceutical compositions comprising such compounds and salts, which are useful as anti-protozoan agents. The invention is also dire...  
WO/2016/168735A1
In various embodiments, a cell culture medium, or a nucleoside cocktail transmission (NCT) medium for the culture of stem cells with improved genetic stability, cellular function and regeneration ability is provided. Illustrative culture...  
WO/2016/168750A1
The present invention provides nucleic acid probes comprising two quenchers of excited state energy, and methods of their use.  
WO/2016/160646A1
The present invention is directed to processs for making Compounds of Formula (II): (II), and salts thereof, wherein B, X, R2, R3, R4 R7, R8 and R9 are defined herein.  
WO/2016/159836A1
The invention relates to the field of organic chemistry and medicine, and more particularly to synthetic substances of the pyrimidine series, namely 2-chloro-5-phenyl-5H-pyrimido[5',4':5,6]pyrano[2,3-d]pyrimid ine-4-ol derivatives, havin...  
WO/2016/160524A1
The invention provides a process for the preparation of nicotinamide mononucleotide having formula (I): The method involves the protection of nicotinamide riboside by ketalization, followed by phosphorylation and then deprotection to pro...  
WO/2016/159374A1
 The present invention provides a method for producing glycoside compounds represented by general formula (I) or salts thereof, said method comprising: a step (step 0) in which a thioether compound represented by general formula (103) ...  
WO/2016/156512A1
A process for preparing a solid crystalline form of sofosbuvir of formula (I) having an X-ray powder diffraction pattern comprising no reflection at 2-theta angles in the range of from 2.0 to 7.8 0 and preferably comprising reflections a...  
WO/2016/155593A1
The present invention relates to a novel compound of 4'-thionucleoside, a preparation method therefor, a pharmaceutical composition comprising the same and an application thereof. Specifically, the present invention relates to a phospham...  
WO/2016/161086A1
The invention provides compositions and methods for treating glycogen storage diseases or conditions with a buildup of glycogen. Cyclic AMP elevator compositions are shown to reduce glycogen storage in affected cells and therefore can be...  
WO/2016/154013A1
HAT-Pi chemotherapy arrests uncontrolled replication and metastatic migration of neoplastic cells by inhibiting enzymatic activity of poly (ADP-ribose) polymerase 1 (PARP 1) through administration of one or more halogenated analogs of th...  
WO/2016/151542A1
The present invention relates to an industrially applicable process for the preparation of phosphoramidates useful for the treatment of viral infections, such as sofosbuvir, and to intermediates useful for the preparation thereof. Formul...  
WO/2016/147185A1
Novel adenosine 5'-thiophosphate derivatives, represented by Formulae (I) or (I*), and salts thereof, represented by Formulae (Ia) and (I*a), as defined in the specification, and uses thereof as antioxidants and/or P2Y1-R agonists, and/o...  
WO/2016/146808A1
The invention relates to a new synthethic process for obtaining compounds of formula (I) from compounds of formula (II) by means of cytidine deaminase enzymes.  
WO/2016/149395A1
Derivatives of nicotinic acid riboside (NAR), nicotinamide riboside (NR), and reduced NAR and NR, including 1-(2', 3', 5'-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinic acid (4a), and compositions containing the same and/or reduced...  
WO/2016/145142A1
This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or t...  
WO/2016/144918A1
A compound of the structure (A), or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.  
WO/2016/014927A3
Provided are crystalline forms of nicotinamide riboside, including a Form I of nicotinamide riboside chloride according to formula (I). Also disclosed are pharmaceutical compositions comprising the crystalline Form I of nicotinamide ribo...  
WO/2016/144660A1
Provided are crystalline forms of nicotinamide riboside, including a Form II of nicotinamide riboside chloride: nicotinamide riboside chloride. Also disclosed are pharmaceutical compositions comprising the crystalline Form II of nicotina...  
WO/2016/140616A1
Compound 1 with the formula I is an HCV antiviral protide, which is surprisingly soluble in ethanol, thereby facilitating the preparation of pharmaceutical formulations, such as adsorbed mesoporous carriers or SEDDS of Pouton Types III o...  
WO/2016/140615A1
Use of a compound represented by formula (1A), or a pharmaceutically acceptable salt thereof, in the therapy of HCV in a mammal or human, wherein the compound of formula 1A is administered in combination with a further HCV antiviral sele...  
WO/2016/138035A1
Methods of conjugating oligonucleotides are provided. The methods may include: activating a terminal of first oligonucleotide using a squarate reagent to produce an activated first oligonucleotide; and binding the first oligonucleotide a...  
WO/2016/135582A1
Compounds of the general Formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.  
WO/2016/138026A1
Compositions and methods in the field of medicine and chemistry are disclosed. Some of the disclosed embodiments are directed to nucleotide compounds, medicinal compositions, as well as processes for their preparation and methods of thei...  
WO/2016/134056A1
The present invention features compounds of e.g. formula (I) effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HC...  
WO/2016/134054A1
The present invention features compounds of e.g. formula (I) effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HC...  
WO/2016/134053A1
The present invention features compounds of e.g. formula I effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HCV ...  
WO/2016/134057A1
The present invention features compounds of e.g. formula (I) effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HC...  
WO/2016/134051A1
The present invention features compounds of e.g. formula I effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HCV ...  
WO/2016/108930A3
Provided are antisense oligonucleotides targeted against bacterial genes involved in biochemical pathways and/or cellular processes, and related compositions and methods of using the oligonucleotides and compositions, alone or in combina...  
WO/2016/130691A1
Disclosed herein is a method for treating heart failure in a subject in need thereof. The method includes administering a therapeutically effective amount of nicotinamide riboside to the subject. The heart failure may be associated with ...  
WO/2016/099982A3
Disclosed are compounds to the treatment of infectious diseases and methods of treating such diseases. The compounds are derivatives of clevudine.  
WO/2016/126734A1
Novel processes for making the N-pyrrazole substituted 2-adenosine derivative regadenoson and a novel polymorph thereof. The novel polymorph of regadenoson designated form H and drug substances and pharmaceutical compositions including t...  
WO/2015/144282A8
The invention relates to an inorganic-organic hybrid compound as an ion compound, composed of an inorganic cation and an organic anion active substance and optionally, an organic anion fluorescent dye.  
WO/2016/120403A1
The present invention relates to a compound of the general formula (1). wherein the pyranose ring is a-D-galactopyranose, A is selected from The compound of formula (1) is suitable for use in a method for treating a disorder relating to ...  
WO/2016/123397A2
The present disclosure provides nucleoside analogs of Formula (I) or (II). The nucleoside analogs may show multiple tautomerism and may increase the mutation of an RNA and/or DNA (be mutagenic) of a virus or cancer cell. The multiple tau...  
WO/2016/120305A1
A compound of formula (I) Or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of sai...  
WO/2016/094677A3
The invention features a mononucleotide comprising a nucleobase bonded to a sugar having a 3'-carbon and a 5'-carbon, where the 5'-carbon is bonded to a phosphorus (V) atom of a phosphate group through an oxygen atom, the phosphorus (V) ...  
WO/2016/112746A1
Disclosed in the present invention is a method for preparing ribofuranose phosphate derivatives, and the preparation steps thereof comprises: coupling starting materials of isopropyl L-alanine hydrochloride, phenol dichlorophosphate and ...  
WO/2016/113335A1
The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal...  
WO/2016/110761A1
An efficient and simple process is provided for producing 1-β-D-arabinofuranosylcytosine or cytarabine wherein cytidine hydrochloride is converted to the corresponding 2,2'- anhydro-1-β-D-arabinofuranosylcytosine hydrochloride by react...  
WO/2016/107289A1
The present invention relates to a method for preparing Sofosbuvir crystal form-6. The method is simple in operation, stable in process condition, good in reproducibility, high in yield rate and high in purity, viscous gel-type products ...  
WO/2016/105449A1
This disclosure provides compounds and compositions for use as analgesics and for the treatment of one or more conditions selected from: pain; psychic pain; psychological pain; psychiatric pain; depression; allodynia; fibromyalgia; fibro...  
WO/2004/094345A8
This invention relates to protected monomers for the synthesis of iRNA agents.  
WO/2016/101782A1
An oxidized β-nicotinamide adenine dinucleotide phosphate and a purification method therefor, specifically comprising the following steps: a. using membrane concentration equipment to perform microfiltration and then nanofiltration on a...  
WO/2016/106050A1
This disclosure relates to N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment and prophylaxis of viral infections.  

Matches 601 - 650 out of 12,743